X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7373) 7373
Publication (597) 597
Book Review (95) 95
Conference Proceeding (61) 61
Book Chapter (39) 39
Book / eBook (15) 15
Newspaper Article (11) 11
Magazine Article (7) 7
Dissertation (6) 6
Trade Publication Article (6) 6
Web Resource (3) 3
Newsletter (2) 2
Data Set (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4314) 4314
index medicus (3123) 3123
platinum (2777) 2777
cisplatin (2311) 2311
animals (2233) 2233
antineoplastic agents - pharmacology (2212) 2212
oncology (2020) 2020
pharmacology & pharmacy (1989) 1989
female (1962) 1962
cancer (1769) 1769
chemotherapy (1510) 1510
cell line, tumor (1374) 1374
cisplatin - pharmacology (1339) 1339
male (1219) 1219
antineoplastic agents - chemistry (1172) 1172
biochemistry & molecular biology (1062) 1062
organoplatinum compounds - pharmacology (1024) 1024
mice (954) 954
middle aged (857) 857
cytotoxicity (832) 832
chemistry, medicinal (790) 790
dna (770) 770
aged (761) 761
platinum complexes (757) 757
apoptosis (721) 721
antineoplastic agents - therapeutic use (688) 688
adult (678) 678
ovarian neoplasms - drug therapy (676) 676
analysis (652) 652
chemistry, multidisciplinary (645) 645
toxicity (639) 639
ligands (636) 636
ovarian cancer (628) 628
organoplatinum compounds - chemistry (619) 619
platinum - chemistry (617) 617
antineoplastic agents - chemical synthesis (599) 599
platinum - pharmacology (598) 598
cell survival - drug effects (593) 593
chemistry, inorganic & nuclear (592) 592
dose-response relationship, drug (573) 573
in-vitro (572) 572
carboplatin (561) 561
drugs (561) 561
rats (550) 550
drug resistance, neoplasm (522) 522
apoptosis - drug effects (518) 518
antineoplastic combined chemotherapy protocols - therapeutic use (484) 484
cell proliferation - drug effects (481) 481
research (481) 481
structure-activity relationship (480) 480
drug screening assays, antitumor (479) 479
molecular structure (472) 472
antineoplastic agents (468) 468
neoplasms - drug therapy (467) 467
tumor cells, cultured (467) 467
resistance (461) 461
care and treatment (460) 460
tumors (458) 458
cisplatin - administration & dosage (436) 436
lung neoplasms - drug therapy (434) 434
treatment outcome (421) 421
antitumor-activity (420) 420
drug resistance (406) 406
oxaliplatin (405) 405
antineoplastic agents - administration & dosage (403) 403
antimitotic agents (399) 399
ovarian neoplasms - pathology (399) 399
carcinoma (398) 398
pharmacology (386) 386
nanoparticles (384) 384
toxicology (384) 384
proteins (377) 377
platinum-based chemotherapy (374) 374
dna - metabolism (373) 373
binding (366) 366
cells (363) 363
article (358) 358
pharmacokinetics (358) 358
cis-diamminedichloroplatinum (355) 355
organoplatinum compounds - chemical synthesis (354) 354
antineoplastic agents - pharmacokinetics (353) 353
pharmacology/toxicology (344) 344
cancer therapies (342) 342
platinum compounds - pharmacology (339) 339
complexes (330) 330
carcinoma, non-small-cell lung - drug therapy (327) 327
platinum compounds (324) 324
lung cancer (323) 323
expression (318) 318
dna - chemistry (314) 314
deoxyribonucleic acid--dna (311) 311
dna damage (309) 309
cisplatin - toxicity (305) 305
paclitaxel (305) 305
cisplatin - therapeutic use (297) 297
antineoplastic agents - adverse effects (295) 295
kinetics (295) 295
cisplatin - chemistry (293) 293
cisplatin - pharmacokinetics (292) 292
models, molecular (291) 291
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7316) 7316
Japanese (64) 64
Russian (28) 28
French (20) 20
German (15) 15
Chinese (14) 14
Spanish (8) 8
Polish (4) 4
Romanian (2) 2
Czech (1) 1
Hungarian (1) 1
Italian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Current Pharmaceutical Design, ISSN 1381-6128, 2010, Volume 16, Issue 16, pp. 1813 - 1825
Journal Article
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 12/2017, Volume 142, pp. 8 - 31
Metallodrugs offer potential for unique mechanism of drug action based on the choice of the metal, its oxidation state, the types and number of coordinated... 
Proteins | Cytotoxicity | Anticancer agents | DNA | CHEMISTRY, MEDICINAL | SACCHARINATE COMPLEX | STRUCTURAL-CHARACTERIZATION | DNA-BINDING PROPERTIES | PT(II) COMPLEXES | SUBSTITUTION-REACTIONS | ANTITUMOR-ACTIVITY | IN-VITRO CYTOTOXICITY | POLYPYRIDYL COMPLEXES | THIOREDOXIN REDUCTASE | CELLULAR PHARMACOLOGY | Humans | Antineoplastic Agents - therapeutic use | Platinum - toxicity | Platinum - chemistry | Ruthenium - chemistry | Antineoplastic Agents - toxicity | Ruthenium - therapeutic use | Coordination Complexes - pharmacology | Antineoplastic Agents - pharmacology | Platinum - pharmacology | Coordination Complexes - toxicity | Gold - toxicity | Gold - chemistry | Ruthenium - toxicity | Platinum - therapeutic use | Palladium - pharmacology | Gold - pharmacology | Antineoplastic Agents - chemistry | Coordination Complexes - chemistry | Drug Discovery | Palladium - toxicity | Ruthenium - pharmacology | Neoplasms - drug therapy | Coordination Complexes - therapeutic use | Animals | Palladium - therapeutic use | Gold - therapeutic use | Palladium - chemistry | Enzymes | Chromosomal proteins | Ruthenium | Thiols | Lung cancer | Leukemia | Albumin | Palladium | Antineoplastic agents | Ethylenediamines | Antimitotic agents | Cytokinins | Chemotherapy | Colon cancer | Gliomas | Prostate cancer | Cervical cancer | Cancer | Protein binding | Index Medicus
Journal Article
Molecules, ISSN 0022-2275, 03/2017, Volume 22, Issue 3, pp. 529 - 542
Journal Article
Cancer Research, ISSN 0008-5472, 07/2017, Volume 77, Issue 14, pp. 3870 - 3884
Effective targeted therapies for small-cell lung cancer (SCLC), the most aggressive form of lung cancer, remain urgently needed. Here we report evidence of... 
GENE | SIGNATURES | ONCOLOGY | BIOLOGY | RESISTANCE | PARP | MODEL | MUTATIONS | IDENTIFICATION | Piperazines - administration & dosage | Lung Neoplasms - drug therapy | Humans | Pyrazines - administration & dosage | Small Cell Lung Carcinoma - enzymology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Cisplatin - administration & dosage | Gene Knockdown Techniques | Biomarkers, Tumor - metabolism | Female | Pyrazoles - pharmacology | Lung Neoplasms - genetics | Phthalazines - administration & dosage | Checkpoint Kinase 1 - antagonists & inhibitors | Small Cell Lung Carcinoma - genetics | Cisplatin - pharmacology | Piperazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Drug Synergism | Checkpoint Kinase 1 - metabolism | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Pyrazoles - administration & dosage | Small Cell Lung Carcinoma - pathology | Animals | Mice, Nude | Cell Line, Tumor | Mice | Pyrazines - pharmacology | Checkpoint Kinase 1 - genetics | Medical research | Cell culture | Effectiveness | Small cell lung carcinoma | RNA-mediated interference | CHK1 protein | Lung cancer | Clinical trials | Poly(ADP-ribose) polymerase | Pharmacology | Myc protein | Kinases | Cisplatin | Anticancer properties | Amplification | Inhibitors | Platinum | Biomarkers | Antitumor activity | Bioindicators | Inhibition | Cancer
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2019, Volume 144, Issue 4, pp. 755 - 766
Bromodomain and Extra‐Terminal (BET) proteins are historically involved in regulating gene expression and BRD4 was recently found to be involved in DNA damage... 
triple negative breast neoplasms | homologous recombination | BRCAness | synthetic lethality | BET inhibitors | BREAST-CANCER | TARGET | OLAPARIB | CARBOPLATIN | ONCOLOGY | PARP INHIBITORS | DEFICIENCY | Humans | RNA Interference | BRCA1 Protein - metabolism | Triple Negative Breast Neoplasms - pathology | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Nuclear Proteins - genetics | Recombinational DNA Repair - drug effects | Rad51 Recombinase - metabolism | Benzodiazepines - pharmacology | Rad51 Recombinase - genetics | Recombinational DNA Repair - genetics | Nuclear Proteins - metabolism | Transcription Factors - antagonists & inhibitors | Cisplatin - pharmacology | Transcription Factors - genetics | Piperazines - pharmacology | Azepines - pharmacology | Transcription Factors - metabolism | Triazoles - pharmacology | BRCA1 Protein - genetics | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Triple Negative Breast Neoplasms - genetics | Triple Negative Breast Neoplasms - metabolism | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | DNA Damage | Salts | Chromatin | Immunoprecipitation | DNA damage | Homologous recombination | Clinical trials | Homology | Lethality | DNA repair | Subgroups | Proteins | Historical account | Platinum | Inhibition | Repair | Deoxyribonucleic acid--DNA | Medical research | Phenotypes | Damage assessment | BRCA1 protein | RNA-mediated interference | Poly(ADP-ribose) polymerase | Breast cancer | Pharmacology | Gene expression | Inhibitors | Ribonucleic acids | Cell death | Cancer
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2014, Volume 9, Issue 1, p. e84248
Since the serendipitous discovery of cisplatin, platinum-based drugs have become well-established antitumor agents, despite the fact that their clinical use is... 
20S PROTEASOME | DESIGN | CANCER CELLS | MULTIDISCIPLINARY SCIENCES | COMPLEXES | OLIGOPEPTIDES | BORTEZOMIB | GOLD(III) DITHIOCARBAMATE DERIVATIVES | PROTEASOME INHIBITORS | COUPLED PEPTIDE TRANSPORTERS | APOPTOSIS INDUCERS | Free Radical Scavengers - pharmacology | Apoptosis - drug effects | Humans | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Peptidomimetics - administration & dosage | Thiocarbamates - pharmacology | Chromans - pharmacology | Organogold Compounds - administration & dosage | Drug Design | Female | Antineoplastic Agents - pharmacology | Molecular Structure | Drug Evaluation, Preclinical | Organogold Compounds - chemistry | Disease Models, Animal | Peptidomimetics - pharmacology | Thiocarbamates - administration & dosage | Proteasome Inhibitors - pharmacology | Peptidomimetics - chemistry | Cisplatin - pharmacology | Thiocarbamates - chemistry | Antineoplastic Agents - chemistry | Breast Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Organogold Compounds - pharmacology | Tumor Burden - drug effects | Breast Neoplasms - pathology | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Proteasome Endopeptidase Complex - metabolism | Chemotherapy | Peptides | Health aspects | Cancer | Drugs | Delivery systems | Clinical trials | Homeostasis | Oncology | Biochemistry | Metastasis | Kinases | Cancer therapies | Anticancer properties | Proteins | Antitumor agents | Platinum | Xenografts | Cell cycle | Inhibition | Sulfur | Gold | Enzymes | Medical research | Departments | Cultures | Breast cancer | Pharmacology | Shrinkage | Cisplatin | Medicine | Pathology | Chemistry | Side effects | Peptidomimetics | Breast | Ligands | Drug discovery | Prostate cancer | Apoptosis
Journal Article
Oncogene, ISSN 0950-9232, 05/2013, Volume 32, Issue 22, pp. 2767 - 2781
Cisplatin and paclitaxel are standard chemotherapy for metastatic ovarian cancer, but with limited efficacy. Cancer stem/progenitor cells (or tumor-initiating... 
b-catenin | chemoresistance | c-Kit | ovarian cancer | ABCG2 | beta-catenin | SURFACE EPITHELIUM | ONCOLOGY-GROUP | BIOCHEMISTRY & MOLECULAR BIOLOGY | PLATINUM-RESISTANT | CHRONIC MYELOID-LEUKEMIA | CELL BIOLOGY | PHASE-II TRIAL | ONCOLOGY | SEROUS CARCINOMA | GENETICS & HEREDITY | IMATINIB MESYLATE | EPITHELIAL OVARIAN | CLINICOPATHOLOGICAL FEATURES | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Paclitaxel - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Tumor Microenvironment | Neoplasm Proteins - metabolism | Proto-Oncogene Proteins c-kit - metabolism | Wnt Proteins - metabolism | Cell Hypoxia | Neoplastic Stem Cells - metabolism | RNA Interference | Cell Transformation, Neoplastic - genetics | ATP-Binding Cassette Transporters - metabolism | Female | Proto-Oncogene Proteins c-kit - genetics | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Ovarian Neoplasms - metabolism | Ovarian Neoplasms - drug therapy | Cell Survival - drug effects | Cisplatin - pharmacology | Pyrimidines - pharmacology | Cell Transformation, Neoplastic - metabolism | Imatinib Mesylate | Piperazines - pharmacology | beta Catenin - metabolism | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Wnt Signaling Pathway - drug effects | Mice, Nude | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | RNA, Small Interfering
Journal Article
Drug Resistance Updates, ISSN 1368-7646, 2016, Volume 27, pp. 72 - 88
Abstract It is now widely accepted that organic anion-transporting polypeptides (OATPs), especially members of the OATP1A/1B family, can have a major impact on... 
Infectious Disease | Hematology, Oncology and Palliative Medicine | OATP1B3 | OATP1A/1B transporters | Drug disposition | Hepatic uptake | OATP1B1 | Drug–drug interactions | RESISTANCE ASSOCIATED PROTEIN-2 | HEPATIC-UPTAKE | CYTOCHROME-P450 3A4 | MOUSE MODELS | P-GLYCOPROTEIN | SORAFENIB-GLUCURONIDE | INTESTINAL-ABSORPTION | CARBOXYLESTERASE DETERMINE BRAIN | IN-VIVO | PHARMACOLOGY & PHARMACY | Drug-drug interactions | Methotrexate - pharmacology | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Taxoids - toxicity | Liver - pathology | Taxoids - pharmacology | Camptothecin - toxicity | Humans | Methotrexate - pharmacokinetics | Hepatocytes - pathology | Methotrexate - toxicity | Hepatocytes - metabolism | Phenylurea Compounds - toxicity | Platinum Compounds - pharmacokinetics | Antineoplastic Agents - toxicity | Drug Interactions | Liver - drug effects | Neoplasms - genetics | Niacinamide - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Phenylurea Compounds - pharmacokinetics | Hepatocytes - drug effects | Organic Cation Transport Proteins - deficiency | Camptothecin - analogs & derivatives | Solute Carrier Organic Anion Transporter Family Member 1b1 - genetics | Camptothecin - pharmacokinetics | Gene Expression | Liver - metabolism | Mice, Transgenic | Doxorubicin - pharmacokinetics | Doxorubicin - toxicity | Neoplasms - drug therapy | Taxoids - pharmacokinetics | Animals | Solute Carrier Organic Anion Transporter Family Member 1b1 - metabolism | Niacinamide - toxicity | Inactivation, Metabolic - genetics | Mice | Phenylurea Compounds - pharmacology | Niacinamide - pharmacology | Neoplasms - pathology | Organic Cation Transport Proteins - genetics | Platinum Compounds - toxicity | Camptothecin - pharmacology | Platinum Compounds - pharmacology | Doxorubicin - pharmacology | Proteins | Tyrosine | Anthracyclines | Analysis | Liver | Heme | Genetic engineering | Bilirubin | Methotrexate | Molecular biology
Journal Article